Identification and characterization of persistent human erythrovirus infection in blood donor samples

Journal of Virology

Volumn 78, Issue 22, 2004, Pages 12169-12178

  Candotti, Daniel ^a,d   Etiz, Nermin ^c   Parsyan, Armen ^b   Allain, Jean Pierre ^b  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Refik Saydam Hygiene Center   (Turkey)

^d Cambridge Blood Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS DNA;

AFRICA; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PARVOVIRUS; PERSISTENT INFECTION; PHYLOGENY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SPECIES COMPARISON; UNITED KINGDOM; VIRUS INFECTION; VIRUS LOAD;

AMINO ACID SEQUENCE; ANTIBODIES, VIRAL; BLOOD DONORS; CAPSID PROTEINS; DNA, VIRAL; ERYTHROVIRUS; HUMANS; MOLECULAR SEQUENCE DATA; PARVOVIRIDAE INFECTIONS;

EID: 7644242099     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.22.12169-12178.2004     Document Type: Article

References (43)

1. Allain, J.-P., D. Candotti, K. Soldan, F. Sarkodie, B. Phelps, C. Giachetti, V. Shyamala, F. Yeboah, M. Anokwa, S. Owusu-Ofori, and O. Opare-Sem. 2003. The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood 101:2419-2425.
2. Aubin, J.-T., C. Defer, M. Vidaud, M. Maniez Montreuil, and B. Flan. 2000. Large-scale screening for human parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionation. Vox Sang. 78:7-12.
3. Blumel, J., I. Schmidt, W. Effenberger, H. Seitz, H. Willkommen, H. H. Brackmann, J. Lower, and A. M. Eis-Hubinger. 2002. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion 42:1473-1481.
4. Brechot, C., V. Thiers, D. Kremsdorf, B. Nalpas, S. Pol, and P. Paterlini-Brechot. 2001. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 34:194-203.
5. Brown, K. E., N. S. Young, B. M. Alving, and L. H. Barbosa. 2001. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion 41:130-135.
6. Candotti, D., C. Mundy, G. Kadewele, W. Nkhoma, I. Bates, and J.-P. Allain. 2001. Serological and molecular screening for viruses in blood donors from Ntcheu, Malawi: high prevalence of HIV-1 subtype C and of markers of hepatitis B and C viruses. J. Med. Virol. 65:1-5.
7. Candotti, D., A. Richetin, B. Cant, J. Temple, C. Sims, I. Reeves, J. A. J. Barbara, and J.-P. Allain. 2003. Evaluation of a transcription-mediated amplification-based HCV and HIV-1 duplex assay for screening individual blood donations: a comparison with a minipool testing system. Transfusion 43:215-225.
8. Candotti, D., J. Temple, S. Owusu-Ofori, and J.-P. Allain. 2004. Multiplex real-time quantitative RT-PCR assay for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1. J. Virol. Methods 118:39-47.
9. Cohen, B. J., and M. M. Buckley. 1988. The prevalence of antibody to human parvovirus B19 in England and Wales. J. Med. Microbiol. 25:151-153.
10. Dorsch, S., B. Kaufmann, U. Schaible, E. Prohaska, H. Wolf, and S. Modrow. 2001. The VP1-unique region of parvovirus B19: amino acid variability and antigenic stability. J. Gen. Virol. 82:191-199.
11. Gallinella, G., S. Venturoli, E. Manaresi, M. Musiani, and M. Zerbini. 2003. B19 virus genome diversity: epidemiological and clinical correlations. J. Clin. Virol. 28:1-13.
12. Gigler, A., S. Dorsch, A. Hemauer, C. Williams, S. Kim, N. S. Young, S. Zolla-Pazner, H. Wolf, M. K. Gorny, and S. Modrow. 1999. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J. Virol. 73:1974-1979.
13. Harder, T. C., M. Hufnagel, K. Zahn, K. Beutel, H.-J. Schmitt, U. Ullmann, and P. Rautenberg. 2001. New LightCycler PCR for rapid and sensitive quantification of parvovirus B19 DNA guides therapeutic decision-making in relapsing infections. J. Clin. Microbiol. 39:4413-4419.
14. Heegaard, E. D., and K. E. Brown. 2002. Human parvovirus B19. Clin. Microbiol. Rev. 15:485-505.
15. Heegaard, E. D., I. P. Jensen, and J. Christensen. 2001. Novel PCR assay for differential detection and screening of erythrovirus B19 and erythrovirus V9. J. Med. Virol. 65:362-367.
16. Heegaard, E. D., B. L. Petersen, C. J. Heilmann, and A. Hornsleth. 2002. Prevalence of parvovirus B19 and parvovirus V9 DNA and antibodies in paired bone marrow and serum samples from healthy individuals. J. Clin. Microbiol. 40:933-936.
17. Heegaard, E. D., K. Qvortrup, and J. Christensen. 2002. Baculovirus expression of erythrovirus V9 capsids and screening by ELISA: serologic cross-reactivity with erythrovirus B19. J. Med. Virol. 66:246-252.
18. Hokynar, K., P. Norja, H. Laitinen, P. Palomaki, A. Garbarg-Chenon, A. Ranki, K. Hedman, and M. Sonderlund-Venermo. 2004. Detection and differentiation of human parvovirus variants by commercial quantitative real-time PCR tests. J. Clin. Microbiol. 42:2013-2019.
19. Hokynar, K., M. Söderlund-Venermo, M. Pesonen, A. Ranki, O. Kiviliuoto, E. K. Partio, and K. Hedman. 2002. A new parvovirus genotype persistent in human skin. Virology 302:224-228.
20. Jordan, J., B. Tiangco, J. Kiss, and W. Koch. 1998. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang. 75:97-102.
21. Kerr, S., G. O'Keeffe, C. Kilty, and S. Doyle. 1999. Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG. J. Med. Virol. 57:179-185.
22. Koppelman, M. H. G. M., H. T. M. Cuypers, T. Emrich, and H. L. Zaaijer. 2004. Quantitative real-time detection of parvovirus B19 DNA in plasma. Transfusion 44:97-103.
23. Kurtzman, G. J., B. J. Cohen, A. M. Field, R. Oseas, R. M. Blaese, and N. S. Young. 1989. Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J. Clin. Investig. 84:1114-1123.
24. Lukashov, V. V., and J. Goudsmit. 2001. Evolutionary relationships among parvoviruses: virus-host coevolution among autonomous primate parvoviruses and links between adeno-associated and avian parvoviruses. J. Virol. 75:2729-2740.
25. Manaresi, E., G. Gallinella, M. Zerbini, S. Venturoli, G. Gentilomi, and M. Musiani. 1999. IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assay. J. Med. Virol. 57:174-178.
26. Manaresi, E., E. Zuffi, G. Gallinella, G. Gentilomi, M. Zerbini, and M. Musiani. 2001. Differential IgM response to conformational and linear epitopes of parvovirus B19 VP1 and VP2 structural proteins. J. Med. Virol. 64:67-73.
27. McOmish, F., P. L. Yap, A. Jordan, H. Hart, B. J. Cohen, and P. Simmonds. 1993. Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J. Clin. Microbiol. 31:323-328.
28. Musiani, M., E. Mnaresi, G. Gallinella, S. Venturoli, E. Zuffi, and M. Zerbini. 2000. Immunoreactivity against linear epitopes of parvovirus B19 structural proteins. Immunodominance of the amino-terminal half of the unique region of VP1. J. Med. Virol. 60:347-352.
29. Nguyen, Q. T., C. Sifer, V. Schneider, X. Allaume, A. Servant, F. Bernaudin, V. Auguste, and A. Garbarg-Chenon. 1999. Novel human erythrovirus associated with transient aplastic anemia. J. Clin. Microbiol. 37:2483-2487.
30. Nguyen, Q. T., S. Wong, E. D. Heegaard, and K. E. Brown. 2002. Identification and characterization of a second novel human erythrovirus variant, A6. Virology 301:374-380.
31. Saikawa, T., S. Anderson, M. Momoeda, S. Kajigaya, and N. S. Young. 1993. Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J. Virol. 67:3004-3009.
32. Sato, H., J. Hirata, N. Kuroda, H. Shiraki, Y. Maeda, and K. Okochi. 1991. Identification and mapping of neutralizing epitopes of human parvovirus B19 by using human antibodies. J. Virol. 65:5485-5490.
33. Schorling, S., G. Schalasta, G. Enders, and M. Zauke. 2004. Quantification of parvovirus DNA using COBAS AmpliPrep automated sample preparation and LightCycler real-time PCR. J. Mol. Diagn. 6:37-41.
34. Schoub, B. D., N. K. Blackburn, S. Johnson, and J. M. McAnerney. 1993. Primary and secondary infection with human parvovirus B19 in pregnant women in South Africa. S. Afr. Med. J. 83:505-506.
35. Servant, A., S. Laperche, F. Lallemand, V. Marinho, G. De Saint Maur, J.-F. Meritet, and A. Garbarg-Chenon. 2002. Genetic diversity within human erythroviruses: identification of three genotypes. J. Virol. 76:9124-9134.
36. Söderlund, M., C. S. Brown, W. J. M. Spaan, L. Hedman, and K. Hedman. 1995. Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19. J. Infect. Dis. 172:1431-1436.
37. Thomas, I., M. Di Giambattista, C. Gerard, E. Mathys, V. Hougardy, B. Latour, T. Branckaert, and R. Laub. 2003. Prevalence of human erythrovirus B19 DNA in healthy Belgian blood donors and correlation with specific antibodies against structural and non-structural viral proteins. Vox Sang. 84:300-307.
38. Tolfvenstam, T., M. Enbom, H. Ghebrekidan, U. Ruden, A. Linde, M. Grandien, and B. Wahren. 2000. Seroprevalence of viral childhood infections in Eritrea. J. Clin. Virol. 16:49-54.
39. Tolfvenstam, T., A. Lundqvist, M. Levi, B. Wahren, and K. Broliden. 2001. Mapping of B-cell epitopes on human parvovirus B19 non-structural and structural proteins. Vaccine 19:758-763.
40. Tsujimura, M., K. Matsushita, H. Shiraki, H. Sato, K. Okochi, and Y. Maeda. 1995. Human parvovirus B19 infection in blood donors. Vox Sang. 69:206-212.
41. Weimer, T., S. Streichert, C. Watson, and A. Gröner. 2001. High-liter screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation. Transfusion 41:1500-1504.
42. Yoto, Y., T. Kudoh, K. Haseyama, N. Suzuki, T. Oda, T. Katoh, T. Takahashi, S. Sekiguchi, and S. Chiba. 1995. Incidence of human parvovirus B19 DNA detection in blood donors. Br. J. Haematol. 91:1017-1018.
43. Zuffi, E., E. Manaresi, G. Gallinella, G. A. Gentilomi, S. Venturoli, M. Zerbini, and M. Musiani. 2001. Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans. Viral Immunol. 14:151-158.